Daily Management Review

Pfizer to sell its healthcare business in November: Sources


10/26/2017


As per Pfizer’s Chief Executive, the core reason for this divestiture is to provide a better return for shareholder’s money: its consumer healthcare is worth more outside the group than within.



According to multiple source close to the matter at hand, Pfizer plans on divesting its $15 billion plus consumer healthcare business in November through an auction.
 
Several global companies, including Reckitt Benckiser and GlaxoSmithKline have expressed interest in bidding for its business, which had a turnover of $3.4 billion last year.
 
The prospective sale, which is being led by Centerview Partners, Guggenheim Securities and Morgan Stanley, was first mooted on October 10, when Pfizer said it was considering strategic options for the unit.
 
However, sources say preliminary discussions with interested parties, including Reckitt, have already taken place.
 
Pfizer wants to get the process started before the end of 2017.
 
On Wednesday, Emma Walmsley, GSK’s Chief Executive had confirmed that she would look “carefully” at the business.
 
As per 3 sources familiar with the situation, GSK has hired Citi to represent it in the auction.
 
GSK declined to comment. Citi was not immediately available for comment.
 
As per several sources, other prospective bidders include, Sanofi, Procter & Gamble, Nestle and Johnson & Johnson.
 
Pfizer plans to send out financial information about the consumer unit to prospective buyers in around three weeks time, said one of the sources, who went on to add, the bidding process is expected to heat up early next year and is expected to be sealed around the middle of 2018.
 
As per a source, Pfizer expects to raise at least $20 billion from this divestiture, given the repertoire of brands the business has in its basket including, painkiller Advil, lip balm Chapstick and multivitamins Centrum.
 
In recent year, with consumers growing increasingly health conscious, demand for medication and the consumer health sector has been a fertile ground for deal-makers.
 
As per Ian Read, Pfizer’s Chief Executive, he intends to sell the consumer healthcare business since it isn’t an integral part to the company’s core prescription drug business and might be worth more outside the group.


References:
reuters.com
 







Science & Technology

DNA Sequencing Project Proposed For All Complex Life Forms On Earth By An Int’l Team

Facebook may start production of its own microprocessors

Long-Term Alcohol Monitoring Could Be Possible With A New Injectable Chip Developed By U.S. Researchers

Sweden Now Has The First Electrified Road In The World

Over 270,000 Account Globally Banned From Twitter For Promotion Of Terrorism

Device Capable Of Hearing The Inner Voice Developed By Researchers

New mobile technologies will warn about natural disasters

The brewing industry welcomes blockchain

Asset-Sharing App Of Ryder Is Meant For Commercial Vehicles

Credit Suisse: China will become the leader in AI sphere

World Politics

World & Politics

Debates over Google are heating as a new EU directive is about to be introduced

Will Merkel accept Macron's plans for Europe?

USA and China are pushing North Korea to denuclearization

Germany's dilemma: Will the atomic energy win?

A Forceful Response To Syria Attack Will Be Given By U.S.: Trump

Is Trump’s Maximum Pressure Tactic On North Korea Succeeding Because Of China?

Why are Turkey-EU relations moving back?

Record-Breaking $39 Million raised for Rare Cancer Research in 2018 by Cycle for Survival